Based on these findings, we speculated that the CEBPβ-p53-TIGAR-PFK1 pathway could play a role in the inhibitory effect of DNASE1L3 on glycolysis by the interaction between DNASE1L3 and CEBPβ in HCC. The gene discussed is DNASE1L3; the disease is hepatocellular carcinoma.